Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition
Brittany Haynes, Junko Murai, Jung‐Min Lee
Cancer Treatment Reviews (2018) Vol. 71, pp. 1-7
Open Access | Times Cited: 105

Showing 1-25 of 105 citing articles:

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong, Yueshan Li, Liang Xiong, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1143
PARP and PARG inhibitors in cancer treatment
Dea Slade
Genes & Development (2020) Vol. 34, Iss. 5-6, pp. 360-394
Open Access | Times Cited: 525
Poly(ADP-ribose) polymerase inhibition: past, present and future
Nicola J. Curtin, Csaba Szabó
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 10, pp. 711-736
Closed Access | Times Cited: 403
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
Patrick G. Pilié, Carl M. Gay, Lauren A. Byers, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 13, pp. 3759-3771
Open Access | Times Cited: 291
The forefront of ovarian cancer therapy: update on PARP inhibitors
Mansoor Raza Mirza, Robert L. Coleman, Antonio González‐Martín, et al.
Annals of Oncology (2020) Vol. 31, Iss. 9, pp. 1148-1159
Open Access | Times Cited: 277
Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy
Yong Fang, Daniel J. McGrail, Chaoyang Sun, et al.
Cancer Cell (2019) Vol. 35, Iss. 6, pp. 851-867.e7
Open Access | Times Cited: 197
The expanding universe of PARP1-mediated molecular and therapeutic mechanisms
Dan Huang, W. Lee Kraus
Molecular Cell (2022) Vol. 82, Iss. 12, pp. 2315-2334
Open Access | Times Cited: 159
The DNA Damaging Revolution: PARP Inhibitors and Beyond
Timothy A. Yap, Ruth Plummer, Nilofer S. Azad, et al.
American Society of Clinical Oncology Educational Book (2019), Iss. 39, pp. 185-195
Closed Access | Times Cited: 157
Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor–resistant cancer
Nitasha Gupta, Tzu‐Ting Huang, Sachi Horibata, et al.
Pharmacological Research (2022) Vol. 178, pp. 106162-106162
Open Access | Times Cited: 75
ADP-ribosylation from molecular mechanisms to therapeutic implications
Marcin J. Suskiewicz, Evgeniia Prokhorova, J.G.M. Rack, et al.
Cell (2023) Vol. 186, Iss. 21, pp. 4475-4495
Open Access | Times Cited: 75
PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them
Dongha Kim, Hye Jin Nam
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8412-8412
Open Access | Times Cited: 71
Recent strategies to overcome breast cancer resistance
Muhammad Muzamil Khan, Satya Siva Kishan Yalamarty, Bharat Ashok Rajmalani, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 197, pp. 104351-104351
Open Access | Times Cited: 18
PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
Man Yee Keung, Yanyuan Wu, Jaydutt V. Vadgama
Journal of Clinical Medicine (2019) Vol. 8, Iss. 4, pp. 435-435
Open Access | Times Cited: 136
New strategies in ovarian cancer treatment
Jung‐Min Lee, Lori M. Minasian, Elise C. Kohn
Cancer (2019) Vol. 125, Iss. S24, pp. 4623-4629
Open Access | Times Cited: 108
Exploiting DNA repair defects in colorectal cancer
Nicole M. Reilly, Luca Novara, Federica Di Nicolantonio, et al.
Molecular Oncology (2019) Vol. 13, Iss. 4, pp. 681-700
Open Access | Times Cited: 107
Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer
Feiyue Zheng, Yi Zhang, Shuang Chen, et al.
Biomedicine & Pharmacotherapy (2020) Vol. 123, pp. 109661-109661
Open Access | Times Cited: 104
Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives
Stefania Cocco, Michela Piezzo, Alessandra Calabrese, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 13, pp. 4579-4579
Open Access | Times Cited: 96
Targeting DNA repair in cancer: current state and novel approaches
Apostolos Klinakis, Dimitris Karagiannis, Θεόδωρος Ράμπιας
Cellular and Molecular Life Sciences (2019) Vol. 77, Iss. 4, pp. 677-703
Closed Access | Times Cited: 81
Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer
Michela Chiappa, Federica Guffanti, Francesco Bertoni, et al.
Drug Resistance Updates (2021) Vol. 55, pp. 100744-100744
Closed Access | Times Cited: 79
Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors
Khanh Do, Bose Kochupurakkal, Sarah Kelland, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 17, pp. 4710-4716
Open Access | Times Cited: 72
Exploiting replication gaps for cancer therapy
Ke Cong, Sharon B. Cantor
Molecular Cell (2022) Vol. 82, Iss. 13, pp. 2363-2369
Open Access | Times Cited: 67
Targeting the replication stress response through synthetic lethal strategies in cancer medicine
Natalie Ngoi, Melissa Pham, David S.P. Tan, et al.
Trends in cancer (2021) Vol. 7, Iss. 10, pp. 930-957
Open Access | Times Cited: 63
Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors
Negesse Mekonnen, Hobin Yang, Young Kee Shin
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 58
PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
Rowan Miller, Karim El-Shakankery, Jung‐Yun Lee
Journal of Gynecologic Oncology (2022) Vol. 33, Iss. 3
Open Access | Times Cited: 39
Targeting the DNA damage response for cancer therapy
Nicola J. Curtin
Biochemical Society Transactions (2023) Vol. 51, Iss. 1, pp. 207-221
Open Access | Times Cited: 35
Page 1 - Next Page

Scroll to top